DxTerity Diagnostics Inc (DxTerity) is a medical device company that offers molecular diagnostic solutions. The company develops genomic tests for disease diagnosis. Its patient clinical research platform and dxcollect fingerstick collection kit are used for population-scale genomic studies. The company's dxdirect technology facilitates the direct blood testing of RNA and DNA. DxTerity’s blood-based genomic tests include radiation exposure dosage index test, radiation toxicity test, and rheumatoid arthritis test. It also offers a curation of bioinformatics databases and analysis of RNA and DNA sequence data. DxTerity is headquartered in Rancho Dominguez, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company DxTerity Diagnostics Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
DxTerity Diagnostics Inc Company Overview
DxTerity Diagnostics Inc Company Snapshot
DxTerity Diagnostics Inc Pipeline Products and Ongoing Clinical Trials Overview
Autoimmune Profile Test - Multiple Sclerosis Product Overview
DxCollect MicroCollection Tube
DxCollect MicroCollection Tube Product Overview
DxCollect MicroCollection Tube Clinical Trial
Dxterity Kit - RA
Dxterity Kit - RA Product Overview
RadTox Test
RadTox Test Product Overview
REDI-Dx High Throughput Radiation Biodosimetry Test System
REDI-Dx High Throughput Radiation Biodosimetry Test System Product Overview
DxTerity Diagnostics Inc - Key Competitors
DxTerity Diagnostics Inc - Key Employees
DxTerity Diagnostics Inc - Locations And Subsidiaries
Head Office
Recent Developments
DxTerity Diagnostics Inc, Recent Developments
Nov 08, 2021: DxTerity Diagnostics announces its OSHA Emergency Temporary Standard (ETS) Compliance-Ready COVID-19 Employer Screening Service
Oct 05, 2020: Hematogenix unites with 19 organizations from the healthcare community to form COVID-19 testing industry consortium
Oct 01, 2020: 19 Organizations from the healthcare community unite to form COVID-19 testing Industry Consortium
Mar 03, 2020: DxTerity receives CE Mark for DxCollect fingerstick blood RNA stabilization device
Oct 21, 2018: DxTerity announces presentations from lupus and multiple sclerosis studies at the 2018 ACR/ARHP Annual Meeting
Jun 07, 2018: DxTerity Announces Preliminary Results from the LIFT Study will be Presented at the 2018 Annual European Congress of Rheumatology
May 29, 2018: DxTerity Diagnostics Receives CE Mark for the REDI-Dx Radiation Biodosimetry Test
Nov 05, 2017: DxTerity Announces Preliminary Results from the BRAVO Study will be Presented at the 2017 ACR/ARHP Annual Meeting
Oct 04, 2016: DxTerity Diagnostics Awarded Up to $150 Million BARDA Contract for Advanced Development and Delivery of REDI-Dx® High Throughput Radiation Biodosimetry Test
Dec 20, 2013: DxTerity’s REDI-Dx Wins 2013 NCT CBRNe Product of the Year Award